Swiss biotech investor Xlife Sciences AG said on Wednesday its portfolio company Veraxa Biotech AG would list on U.S.

Y-mAbs Therapeutics (YMAB) stock drops as Bank of America downgrades the company citing challenges for its only approved drug ...

Bicara Therapeutics shows potential to reshape cancer care with ficerafusp alfa and robust funding post-IPO. Find out why ...